Petition update

Collusion to Control the Narrative (Part 2)

Carl Tuttle
Hudson, NH, United States

Oct 12, 2017 — Oct 12, 2017

Moore Leonhardt & Associates LLC
67 Russ Street
2nd Floor
Hartford, CT 06106
Attn: Attorney Mary Alice Moore Leonhardt

Dear Attorney Moore Leonhardt,

For the record, there has been no response from the lead author of the commentary,
False and Misleading Information about Lyme Disease after multiple attempts have gone unanswered. (See inquiry below)

The three authors of this commentary have spent their careers discrediting the sick and disabled along with the clinicians attempting to help these patients [1] while trivializing a disease capable of ruining lives.

The suppression of evidence of persistent infection and seronegative disease has kept this life-altering/life-threatening infection classified as a low-risk and non-urgent health issue.

The following quote is from a professor (Lyme researcher) who, for the moment, will remain anonymous:

Oct 2, 2017

The "common knowledge" about Borrelia is far too heavily controlled by a subset of physicians who seem exceedingly selective in acknowledging the literature - as your literature review highlights.

Someone needs to hold accountable those using science to advance their own agenda. Thank you!

The truth about Lyme disease with its life-altering consequences is controlled through editorial censorship and this is blatantly obvious as you have observed through my communication with the Editor-in-Chief of the American Journal of Medicine.

Sincerely,

Carl Tuttle

Reference:

[1] Antiscience and ethical concerns associated with advocacy of Lyme disease
http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(11)70034-2/abstract

First inquiry to Shapiro with no response:

---------- Original Message ----------
From: Carl Tuttle
To: eugene shapiro
Cc: gary wormser , inquire@aldf.com
Date: September 14, 2017 at 11:07 AM
Subject: False and Misleading Information about Lyme Disease


False and Misleading Information about Lyme Disease
Eugene D. Shapiro, M.D., Phillip J. Baker, Ph.D., Executive Director, Gary P.
Wormser, M.
http://www.amjmed.com/article/S0002-9343(17)30138-9/fulltext

Excerpt:

“Because it takes several weeks for antibodies to develop, many patients with Lyme disease will be seronegative early in the illness. However, patients who have been infected by B. burgdorferi for many weeks or months are almost invariably seropositive by 2-tier tests.4”

Sept 14, 2017

Department of Pediatrics
Yale University School of Medicine
333 Cedar Street
P. O. Box 208064
New Haven, Connecticut 06520-8064
Attn: Eugene D Shapiro, MD Professor of Pediatrics and Epidemiology

Dear Dr. Shapiro,

50% of patients identified with the recently discovered Borrelia mayonii (Mayo Clinic) did not test positive using the CDC’s two tier algorithm. Another pathogenic strain, Borrelia miyamotoi is not detected through current serology. Prof. Kerry Clark’s discovery of additional strains in the South are not detected:

UNF Professor Discovers Two Lyme Disease Bacteria Previously Unknown to Infect Human Patients
http://www.infectioncontroltoday.com/news/2014/05/unf-professor-discovers-two-lyme-disease-bacteria-previously-unknown-to-infect-human-patients.aspx

Quote:

“Current testing methods and interpretation criteria, designed to detect just one species (B. burgdorferi), may explain many of the complaints involving the unreliability of Lyme disease tests in the U.S.”
_________________

In 2013 the CDC provided 52 blind-coded archived serum samples including 12 from posttreatment and 20 pretreatment clinically suspect Lyme disease patients, and 20 negative serum samples to Milford Molecular Diagnostics for the purpose of evaluating the accuracy of a new diagnostic test for Lyme disease by Nested PCR and DNA Sequencing, under CDC MTA Reference: NCEZID-R137154-00 and NCEZID-R147284-00.

Dr. Lee’s technology uncovered a novel Borrelia in one of the serum samples tied to a patient in the Hudson Valley, who had been previously treated for neurologic Lyme disease (DNA sequence deposited in GenBank under accession number KM052618) Dr. Lee also found Borrelia miyamotoi in one of the CDC’s serum samples. We have no idea if this new species of Borrelia can be detected by current FDA approved antibody tests.

When Dr. Lee published his findings all communication stopped with the CDC as they refused to respond.

Detection of Borreliae in Archived Sera from Patients with Clinically Suspect Lyme Disease
http://www.mdpi.com/1422-0067/15/3/4284

Untreated strep throat leads to rheumatic fever which can cause irreversible heart damage but rapid culture tests for strep available in the primary care setting has virtually eliminated rheumatic fever and the life-threatening complications associated with that disease.

Misdiagnosed and untreated Lyme disease creates the same life-altering/life-threatening consequences but this has been hidden from the worldwide medical community and general population. Just ask Duke University Professor Neil Spector who required a heart transplant after his Lyme infection went four years untreated. Spector’s laboratory tests (serology) were repeatedly negative. Faulty/misleading antibody tests are the root cause of unimaginable pain and suffering.
(Dr. Neil Spector Phone (919) 684-0409)

Please see the attached PDF referencing “Seronegativity in Lyme borreliosis and Other Spirochetal Infections” 16 September 2003

https://www.dropbox.com/s/3d6m45jzlhhwalu/Seronegativity.pdf?dl=0

Question for Dr. Shapiro:

With all the evidence pointing to seriously flawed Lyme disease testing, why do you and your coauthors continue to promote antiquated antibody tests to disingenuously claim current serology “accurate”?

What is the motivation behind the censorship of the truth and deliberate distortion of the facts?

A response to this serious inquiry is requested.

Sincerely,

Carl Tuttle
Lyme Endemic Hudson, NH

Cc:
Jane Grochowski, Senior Publisher, Elsevier
Thomas Reller, Elsevier Vice President, Global Corporate Relations
Iratxe Puebla, COPE Complaints Administrator, Committee on Publication Ethics (COPE)
Ivan Oransky, President, Center for Scientific Integrity Inc. (Retraction Watch)
Joseph Alpert, MD, Editor in Chief, American Journal of Medicine
Scott Becker, Executive Director, Association of Public Health Laboratories
Peter Salovey, President, Yale University
Mary Alice Moore Leonhardt, Moore Leonhardt & Associates LLC

Note: We know that antibodies are not produced for 4-6 weeks after a tick bite. The lack of early diagnostic tests for Lyme disease has caused untold pain and suffering worldwide as delayed diagnosis and treatment often leads to "chronic Lyme disease"

Second inquiry to Shapiro with no response:

--------- Original Message ----------
From: Carl Tuttle
To: eugene shapiro
Cc: gary wormser , Executivedir@aldf.com
Date: September 17, 2017 at 8:45 AM
Subject: Re: False and Misleading Information about Lyme Disease

Dr. Shapiro,

You have yet to respond to my questions presented in the email below dated Sept 14, 2017.

What do you stand to gain from promoting what is widely acknowledged as a highly insensitive testing approach that is also acknowledged as being designed for surveillance purposes (thus weighted heavily towards specificity, not sensitivity in this situation) as the “gold standard” for diagnostic purposes. Surveillance case definition criteria was not intended for treatment decisions yet physicians that diagnose on clinical presentation and history continue to be persecuted for diagnosing and treating patients that fail to meet the laboratory confirmation portion of the surveillance criteria. Patients cannot get properly diagnosed and treated for an infection capable of destroying lives.

Let me remind you Dr. Shapiro that scientific misconduct to support one’s bias is fraud. Suppressing evidence of persistent infection and seronegative disease appears to be commonplace for you and your coauthors.

I would like to call attention to a recently published paper (Aug 24, 2017) published by colleagues of Dr. Gary Wormser at New York Medical College and the Centers for Disease Control identifying the ability of the Lyme disease spirochete to withstand lethal doses of antibiotics.

Quote from the article: “The metabolic and morphologic changes resulting from activation of the stringent response in B. burgdorferi may also be involved in the recently described non-genetic phenotypic phenomenon of tolerance to otherwise lethal doses of antimicrobials and to other antimicrobial activities.”

LYME SCI: Do sleeper cells hold key to “turning off” Borrelia?
https://www.lymedisease.org/lyme-sleeper-cells/?utm_source=sept+9--sleeper&utm_campaign=sept+5--sleeper+cells&utm_medium=email

Outstanding questions for Dr. Shapiro:

1. With all the evidence pointing to seriously flawed Lyme disease testing, why do you and your coauthors continue to promote antiquated antibody tests to disingenuously claim current serology “accurate”?

2. What is the motivation behind the censorship of the truth and deliberate distortion of the facts?

Please provide a response to these two questions.

Carl Tuttle
Hudson, NH

“Justice will not be served until those who are unaffected are as outraged as those who are.”
― Benjamin Franklin

Lyme Disease: Call for a “Manhattan Project” to Combat the Epidemic
Raphael B. Stricker, Lorraine Johnson

Published: January 02, 2014 DOI: 10.1371/journal.ppat.100379
http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1003796

Cc:
Jane Grochowski, Senior Publisher, Elsevier
Thomas Reller, Elsevier Vice President, Global Corporate Relations
Iratxe Puebla, COPE Complaints Administrator, Committee on Publication Ethics (COPE)
Ivan Oransky, President, Center for Scientific Integrity Inc. (Retraction Watch)
Joseph Alpert, MD, Editor in Chief, American Journal of Medicine
Scott Becker, Executive Director, Association of Public Health Laboratories
Peter Salovey, President, Yale University
Mary Alice Moore Leonhardt, Moore Leonhardt & Associates LLC Mihail Grecea, Ph.D. Expert in Publishing Ethics, Elsevier


Keep fighting for people power!

Politicians and rich CEOs shouldn't make all the decisions. Today we ask you to help keep Change.org free and independent. Our job as a public benefit company is to help petitions like this one fight back and get heard. If everyone who saw this chipped in monthly we'd secure Change.org's future today. Help us hold the powerful to account. Can you spare a minute to become a member today?

I'll power Change with $5 monthlyPayment method

Discussion

Please enter a comment.

We were unable to post your comment. Please try again.